Anagrelide Hydrochloride(an agh’ rah lide)
Agrylin
PREGNANCY CATEGORY C
Drug class
Antiplatelet drug
Therapeutic Actions
Thought to reduce platelet production by decreasing megakaryocyte hypermaturation; inhibits cyclic AMP and ADP collagen-induced platelet aggregation. At therapeutic doses has no effect on WBC counts or coagulation parameters; may affect RBC parameters.
Indications
Treatment of essential thrombocythemia secondary to myeloproliferative disorders to reduce elevated platelet count and the risk of thrombosis and to improve associated symptoms, including thrombohemorrhagic events
Contraindications and Cautions
Contraindicated with known allergy to anagrelide or severe hepatic or renal impairment.
Use cautiously with renal or hepatic disorders, pregnancy, lactation, known heart disease, thrombocytopenia.
Available Forms
Capsules—0.5, 1 mg
Dosages
Adults
Initially, 0.5 mg PO qid or 1 mg PO bid. After 1 wk, reevaluate and adjust the dosage as needed. Dosage is based on platelet counts; goal is less than 600,000 mm3. Do not increase by more than 0.5 mg/day each week. Maximum dose, 10 mg/day or 2.5 mg as a single dose.
Pediatric patients
Initially, 0.5 mg/day–0.5 mg qid. Adjust to lowest effective dose to keep platelet count below 600,000/mm3. Do not increase by more than 0.5 mg/day each week. Maximum dose, 10 mg/day or 2.5 mg in a single dose.
Patients with moderate hepatic impairment
Initially, 0.5 mg/day for at least 1 wk. Monitor patient closely. Do not increase dose by more than 0.5 mg/day in 1 wk.
